LSI - Life Science Intelligence™

LSI Alumni Weekly Recap is out now!

Featured in this week’s recap:

@AdagioMedical
Avisi Technologies
@BerlinHeals
@CapsMedical
@Dasisimulations
@Field_Medical_
@_INNITIUS
@lightHearted_AI
@NaluMed
@neurentmedical
@Neuroelectrics
@oxmedprod
@pleuraldynamics
@Pulse_Bio
@remedyrobotics
Smartlens

Read the full recap here: lifesciencemarketresearch.com/insights/the-w…

Amira Romani’s full keynote from LSI Europe ‘25 is now available.

Amira Romani is Head of Innovation Strategy at @SiemensHealth and leads the global innovation ecosystem Siemens Healthineers SHIFT. In this role, she drives international collaboration with partners from research, industry, start-ups, and policy on key topics such as digital transformation, sustainability, and health equity. She also initiates and supports strategic consortium projects—such as improving stroke care in Europe—to foster impactful innovation in healthcare.

This session was moderated by Joe Mullings, Chairman & CEO of @MullingsGroup.

Watch the full session now on our website and YouTube channel.

RevBio (#LSIAlumni) announced that it has been awarded a $2.2 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH).

This two-year grant builds upon the work that was completed in a prior Phase I grant and will enable the company to complete preclinical product testing which is a key development step for obtaining approval from the FDA to initiate a human clinical trial.

Congratulations to Founder and CEO Brian Hess and the entire @RevBio_ team on another major milestone!

Acorai (#LSIAlumni) announced positive results in a 1,600-patient CAPTURE-HF study for its AI-powered non-invasive platform for improved heart failure patient management.

Congratulations to CEO Filip Peters and the entire Acorai team on this impressive milestone.

Read more: prnewswire.com/news-releases/…

Neuronoff (#LSIAlumni) announced the closure of an oversubscribed $4.5 million financing round to advance its Injectrode® platform toward FDA clearance and commercial launch.

The funding supports scaling production to 1,000 units annually and preparing for a limited U.S. launch in 2026 targeting interventional pain physicians, spinal surgeons, podiatrists, and other specialties treating chronic pain.

Congratulations to CEO Manfred Franke and the entire @Neuronoff team on this successful raise!